Loading
NASDAQHealthcareBiotechnology
Latest quote
$11.21
+$0.20 · +1.82%
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
Previous close
$11.21
+$0.20 · +1.82%
After-hours
$11.21
$0.00 · 0.00%
Oct 7, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
Day range
Current $11.21
52-week range
Current $11.21
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
47
Fair Value
Sentiment
55
Mixed
Risk
59
Elevated Risk
Momentum
36
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
Day range
Current $11.21
52-week range
Current $11.21
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 244.06M USD | 3.55M USD | 151K USD | — | 20.1M USD |
| Cost of goods sold | 1.51M USD | — | — | — | — |
| Gross profit | 242.55M USD | 3.55M USD | 151K USD | — | 20.1M USD |
| Research and development | 129.64M USD | 173.63M USD | 135.26M USD | 87.27M USD | 55.14M USD |
| Selling, general, and administrative | 46.85M USD | 40.75M USD | 34.83M USD | 27.53M USD | 21.33M USD |
| Operating expenses | 171.93M USD | 214.38M USD | 170.09M USD | 114.79M USD | 76.47M USD |
| Interest income | — | — | — | 1K USD | — |
| Interest expense | — | — | — | 1K USD | 4K USD |
| Depreciation and amortization | 1.51M USD | 1.23M USD | 815K USD | 674K USD | 378K USD |
| Operating income | 70.62M USD | −210.83M USD | −169.94M USD | −114.79M USD | −56.37M USD |
| Net income | 87.01M USD | −187.35M USD | −152.99M USD | −104.68M USD | −58.74M USD |
Company facts updated Oct 8, 2026.
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI6.6M0.00%2.3T USD0.03%$381.03-0.40%
iShares Russell 2000 ETFIWM5.3M0.01%78.56B USD0.19%$277.7-1.29%
Vanguard Extended Market ETFVXF2.58M0.00%95.4B USD0.05%$233.49-1.56%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV1.79M0.01%26.69B USD0.33%$37.79-1.23%
iShares Biotechnology ETFIBB1.52M0.01%10.4B USD0.44%$203.34+0.12%
EA Bridgeway Omni Small-Cap Value ETFBSVO1.19M0.05%2.37B USD0.45%$28.29-0.90%
Vanguard Russell 2000 ETFVTWO1.17M0.01%18B USD0.06%$112.21-1.26%
Schwab U.S. Small-Cap ETFSCHA1.13M0.01%22.01B USD0.03%$32.61-1.47%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFU.S. Small Cap Value Portfolio ETF Class SharesDFSViShares Biotechnology ETFIBBEA Bridgeway Omni Small-Cap Value ETFBSVOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
